BLOOMFIELD, Conn., July 27, 2023 /PRNewswire/ -- In response to recent media misrepresentations, Cigna Healthcare, the health benefits provider of The Cigna Group (NYSE: CI), today shared information about one of its processes used to expedite payments to health care clinicians for a small number of relatively low-cost procedures. Cigna believes that the inaccurate portrayal of the PxDx – or "procedure to diagnosis" – process may lead to confusion or misunderstanding about how it works and how it is used.
Here are the facts about this claims review process:
More information about this claims review process is available here.
About Cigna Healthcare
Cigna Healthcare is a health benefits provider that advocates for better health through every stage of life. We guide our customers through the health care system, empowering them with the information and insight they need to make the best choices for improving their health and vitality. Products and services are provided exclusively by or through operating subsidiaries of The Cigna Group (NYSE:CI), including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Health companies or their affiliates and Express Scripts companies or their affiliates. Such products and services include an integrated suite of health services, such as medical, dental, behavioral health, pharmacy, vision, supplemental benefits, and others. Learn more at cignahealthcare.com.
Media contact:
Justine Sessions
This email address is being protected from spambots. You need JavaScript enabled to view it.
860-810-6523
Last Trade: | US$300.73 |
Daily Change: | -5.40 -1.76 |
Daily Volume: | 1,067,621 |
Market Cap: | US$80.270B |
June 12, 2025 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load